Anthera Pharmaceuticals Inc. (NASDAQ:ANTH) fell 3.1% during trading on Monday . The stock traded as low as $3.61 and last traded at $3.69, with a volume of 578,609 shares. The stock had previously closed at $3.81.

Several research firms have recently commented on ANTH. Zacks Investment Research upgraded shares of Anthera Pharmaceuticals from a “hold” rating to a “buy” rating and set a $4.50 price objective for the company in a research note on Tuesday, April 26th. Jefferies Group reissued a “buy” rating on shares of Anthera Pharmaceuticals in a report on Thursday, June 9th. HC Wainwright began coverage on shares of Anthera Pharmaceuticals in a report on Friday. They set a “buy” rating and a $10.00 target price for the company. Finally, FBR & Co reissued a “hold” rating on shares of Anthera Pharmaceuticals in a report on Monday, June 20th. Two analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. Anthera Pharmaceuticals has an average rating of “Buy” and an average price target of $9.58.

The firm’s market capitalization is $150.83 million. The stock has a 50-day moving average of $3.38 and a 200 day moving average of $3.52.

Anthera Pharmaceuticals (NASDAQ:ANTH) last announced its earnings results on Monday, May 9th. The biopharmaceutical company reported ($0.29) earnings per share for the quarter, missing the consensus estimate of ($0.28) by $0.01. Equities analysts forecast that Anthera Pharmaceuticals Inc. will post ($1.25) EPS for the current year.

Anthera Pharmaceuticals Inc (Anthera) is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation and autoimmune diseases. The Company’s primary Phase 3 product candidate blisibimod targets elevated levels of Bcell activating factor (BAFF) which has been associated with a variety of Bcell mediated autoimmune diseases including systemic lupus erythematosus or lupus IgA nephropathy lupus nephritis multiple myeloma and others.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.